Compare Alliant Energy Corporation (LNT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs BIO-TECHNE Corp — how do they compare? Alliant Energy Corporation trades at $73.98 (market cap $19.10B), while BIO-TECHNE Corp trades at $71.52 (market cap $11.16B). The key difference: Alliant Energy Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| LNT | TECH | |
|---|---|---|
Market Cap | $19.10B | $11.16B |
Sector | Utilities | Health |
52-Week High | $78.03 | $72.12 |
52-Week Low | $63.62 | $43.31 |
Enterprise Value | $30.83B | $11.24B |
Dividend Yield | 2.89% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $73.96, down 1.16% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $78.50. The company reported Q1 2026 EPS of $0.82, beating expectations, and maintains a net income margin of 18.58%. Recent news highlights its $13.4 billion clean energy investment plan aimed at capitalizing on data center demand growth.
The outlook for LNT is positive, supported by steady earnings growth, a strong dividend yield, and strategic investments in renewable energy. Key risks include rising debt levels and exposure to regulatory changes in the utilities sector. Analyst sentiment is bullish with no sell ratings, indicating confidence in the company's long-term growth trajectory.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
